Approaching clinical proteomics: current state and future fields of application in fluid proteomics

Autor: Hans-Werner Mewes, Charalampos Aslanidis, Andreas Thiel, Andreas O. H. Gerstner, Joachim Thiery, Rolf Apweiler, Wolfgang Mutter, Christoph Wagener, Jens Hansen, Edmund Maser, Friedrich Lottspeich, Peter Nollau, Andreas Radbruch, Michael J. Taussig, Oswald Wagner, Gregor Rothe, Fredrik Pontén, Thomas Deufel, Michael Neumaier, Stefan Müllner, Gerd Schmitz, Helmut E. Meyer, Marius Ueffing, Wiltrud Verhuven, Knut Reinert, Attila Tárnok, Hans G. Nothwang, Hannes Stockinger, Dennis Hochstrasser, Joël Vandekerckhove, Markus Kubicek, Roland Kellner, G. Valet
Rok vydání: 2009
Předmět:
Proteomics
Clinical Medicine/*methods/standards/trends
FLOW-CYTOMETRIC ASSAYS
Standardization
2-DIMENSIONAL GEL-ELECTROPHORESIS
Computer science
ENHANCED LASER-DESORPTION/IONIZATION
Clinical Biochemistry
Body Fluids/*chemistry
cerebrospinal fluid (CSF)
Computational biology
PROTEIN-PROTEIN INTERACTIONS
Biological variation
surface-enhanced laser desorption/ionization (SELDI)
Medicine and Health Sciences
mass spectrometry (MS)
MAGNETIC BEAD SEPARATION
ddc:576
BRONCHOALVEOLAR LAVAGE FLUID
TRANSITIONAL-CELL CARCINOMA
Proteomics/*methods/standards/trends
standard operating procedures (SOP)
FLIGHT-MASS-SPECTROMETRY [KeyWords Plus]
Biochemistry (medical)
Proteins/*analysis
fluid proteomics
Proteins
DESORPTION-IONIZATION-TIME
General Medicine
preanalytical effects
Diagnostic strategy
Body Fluids
clinical proteomics
INTRA-INDIVIDUAL VARIATION
Spectrometry
Mass
Matrix-Assisted Laser Desorption-Ionization
Proteome
Protein microarray
Biomarker (medicine)
Biological Markers/analysis
Sample collection
matrix assisted laser desorption/ionization (MALDI)
Clinical Medicine
Biomarkers
Zdroj: Clinical Chemistry and Laboratory Medicine, Vol. 47, No 6 (2009) pp. 724-744
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
ISSN: 1437-4331
1434-6621
Popis: The field of clinical proteomics offers opportunities to identify new disease biomarkers in body fluids, cells and tissues. These biomarkers can be used in clinical applications for diagnosis, stratification of patients for specific treatment, or therapy monitoring. New protein array formats and improved spectrometry technologies have brought these analyses to a level with potential for use in clinical diagnostics. The nature of the human body fluid proteome with its large dynamic range of protein concentrations presents problems with quantitation. The extreme complexity of the proteome in body fluids presents enormous challenges and requires the establishment of standard operating procedures for handling of specimens, increasing sensitivity for detection and bioinformatical tools for distribution of proteomic data into the public domain. From studies of in vitro diagnostics, especially in clinical chemistry, it is evident that most errors occur in the preanalytical phase and during implementation of the diagnostic strategy. This is also true for clinical proteomics, and especially for fluid proteomics because of the multiple pretreatment processes. These processes include depletion of high-abundance proteins from plasma or enrichment processes for urine where biological variation or differences in proteolytic activities in the sample along with preanalytical variables such as inter- and intra-assay variability will likely influence the results of proteomics studies. However, before proteomic analysis can be introduced at a broader level into the clinical setting, standardization of the preanalytical phase including patient preparation, sample collection, sample preparation, sample storage, measurement and data analysis needs to be improved. In this review, we discuss the recent technological advances and applications that fulfil the criteria for clinical proteomics, with the focus on fluid proteomics. These advances relate to preanalytical factors, analytical standardization and quality-control measures required for effective implementation into routine laboratory testing in order to generate clinically useful information. With new disease biomarker candidates, it will be crucial to design and perform clinical studies that can identify novel diagnostic strategies based on these techniques, and to validate their impact on clinical decision-making. Clin Chem Lab Med 2009;47:724–44.
Databáze: OpenAIRE
Externí odkaz: